Health Care

Next Weeks Broker Price Targets For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Next Weeks Broker Price Targets For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Boasting a price of $91.92, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded -0.48% lower on the day. They now have a $92.95 price objective on the pharmaceutical company's stock, down from their previous price objective of $115.00. The volatility in the previous week has experienced by 1.85% and observed of 2.32% in the previous month.96.60% ownership is held by institutional investors while insiders hold ownership of 0.50%.

Several investment firms issued their expert ratings on Vertex Pharmaceuticals Incorporated (VRTX) in which Oppenheimer Initiates Coverage On Vertex Pharmaceuticals Incorporated (VRTX) to Perform with no specific Price Target on 12/15/16. Robert W. Baird reiterated a "buy" rating and set a $115.00 price target on shares of Vertex Pharmaceuticals in a report on Monday, January 9th. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. BMO Capital Markets reiterated a "market perform" rating and set a $88.00 price target on shares of Vertex Pharmaceuticals in a report on Wednesday, November 30th. Eight equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, seven equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $110.30. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $103.73.

Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of 22.84 Billion.

ED attaches Rs 18.37 crore assets of Zakir Naik's IRF
The court said the Ministry of Home Affairs (MHA) had sufficient material for the immediate ban. They include forcible conversions and also indoctrination of youth who took to terror.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, January 25th. The pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.29 by $0.06. The business earned $458.71 million during the quarter, compared to the consensus estimate of $453.40 million.

In the profitability analysis, net profit margin of the firm was recorded at -6.60% and operating profit margin was calculated at 0.60% while gross profit margin was measured as 87.90%. On average, analysts predict that Vertex Pharmaceuticals will post $1.62 earnings per share for the current year.

Vertex Pharmaceuticals Incorporated (VRTX) now has a consensus Price Target of $99.7. If you are viewing this piece of content on another site, it was stolen and reposted in violation of United States and global trademark & copyright legislation. The company has a consensus rating of "Hold" and a consensus price target of $100.88. We also noted a 2016-11-21 transaction in which DF Director Mailloux J Wayne sold 5,886 shares at a stock price of $20, carrying a total value of $117720, after which, this insider's investment stands at 101,944 shares, with an overall financial value of $1911450. In a transaction dated February 13, 2017, the shares were put up for sale at an average price of $87.68, raking in a sum of $561,415. Following the completion of the transaction, the director now directly owns 276,225 shares in the company, valued at $22,783,038. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joshua S. Boger sold 6,500 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, December 29th.

India denied by Australia grit, third Test ends in draw
The first hour of the day was stonewalled, with Australia scoring only 25 runs and rightfully so. Handscomb survived a scare on six when his flick to short leg was almost caught by Karun Nair.

Fortive Corporation (NYSE:FTV) ended its day at $59.51 with the rising stream of -0.32% and its total traded volume was 1.42 million shares less than the average volume. Following the completion of the sale, the director now owns 274,725 shares of the company's stock, valued at $20,373,606. The disclosure for this sale can be found here. The stock had a trading volume of 2,501,509 shares.

Shares of Vertex Pharmaceuticals Incorporated closed the previous trading session at 92.36 down -2.21 -2.34% with 1,449,700 shares trading hands. IFM Investors Pty Ltd acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at about $233,000. Capstone Asset Management Co. increased its stake in Vertex Pharmaceuticals by 1.9% in the third quarter. BlackRock Fund Advisors now owns 6,262,876 shares of the pharmaceutical company's stock worth $546,185,000 after buying an additional 234,950 shares in the last quarter. Capital World Investors raised its position in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Finally, Creative Planning increased its stake in Vertex Pharmaceuticals by 5.8% in the third quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,400 shares of the pharmaceutical company's stock worth $103,000 after buying an additional 100 shares during the last quarter.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment.

Stocks under Discussion: Eldorado Gold Corporation (EGO), Palo Alto Networks, Inc. (PANW)
The company has a market cap of $2,214 million and the number of outstanding shares has been calculated to be 716,587,130 shares. The stock is now moving above its 20-Day Simple Moving Average of -8.34% with the 50-Day Simple Moving Average of -8.34 percent.